Evaluate mammography AI tools by FDA status, modality, breast-density evidence, PACS workflow, privacy, false positives, and radiologist review.
Representative source image: official iCAD ProFound AI product page.
Quick answer: Mammography AI tools can assist radiologists with breast cancer detection, case scoring, density assessment, worklist prioritization, priors, and digital breast tomosynthesis review. Evaluate the exact product version, FDA or local authorization, supported modality, scanner compatibility, image privacy, evidence by breast density and population, false-positive burden, and radiologist review workflow before using outputs clinically.
Who this guide is for
Breast imaging centers, radiology groups, women's health programs, screening networks, and health-system AI governance teams comparing mammography AI.
What makes this workflow different
Mammography AI products can support 2D screening, digital breast tomosynthesis, lesion marks, density assessment, triage, priors, risk, and worklists, so buyers need module-specific checks before vendor comparison.
What to verify before using it
Separate 2D mammography, digital breast tomosynthesis, lesion detection, density assessment, risk scoring, priors, worklist triage, and reporting support because each module can have different authorization and workflow risk.
Verify FDA 510(k), CE, UKCA, investigational, or local status for the exact version, modality, geography, workstation, and intended user before clinical use.
Map mammography image routing, DICOM metadata, PACS and worklist integration, cloud processing, support access, retention, BAA or DPA terms, and audit logs before sending studies.
Review validation by breast density, age, scanner vendor, 2D versus DBT modality, cancer prevalence, recall rate, false positives, false negatives, reading time, and subgroup performance.
Define radiologist override, second-reader policy, callback ownership, patient communication boundaries, missed-cancer review, downtime workflow, and post-deployment monitoring before launch.
Risk level and safe use
Medical risk
High
Best first step
Write the workflow in one sentence, decide who reviews the AI output, and test with a small controlled pilot before expanding.
Recommended posture
Use AI as supervised workflow support. Verify sources, privacy, human review, and regulatory fit before relying on outputs.
Source-backed products for this workflow
These profiles are not rankings. They are starting points for checking vendor claims, privacy terms, FDA or regulatory posture, evidence, and workflow fit.
iCAD describes ProFound breast-health AI for 2D and 3D mammography detection, density, scorecard, and risk-related workflows; its product and FDA-clearance materials distinguish cleared detection products from risk features that require product-specific status review.
Best for
Breast imaging programs comparing AI assistance for 2D mammography, digital breast tomosynthesis, case prioritization, and mammography workflow support.
First check
Which module is in scope: ProFound Detection, ProFound AI for DBT, density assessment, risk scoring, or another breast-health workflow.
MammoScreen describes a 2D and 3D FDA-cleared breast cancer screening AI solution with pre-check, priors, pre-reporting, and scoring workflows; Therapixel and FDA materials list MammoScreen clearances including K192854, K243679, K241561, and K243685 for detection or breast-density software.
Best for
Breast imaging programs comparing FDA-cleared and CE-marked mammography AI for detection support, priors, pre-check, and reporting workflow.
First check
Whether the exact MammoScreen version and module are cleared or available for the intended country, modality, and mammography system.
DeepHealth describes Breast Suite as a modular AI-powered breast imaging suite; its product page notes FDA 510(k) clearance K251873 for Saige-Dx while also labeling some modules as pending clearance or not cleared for U.S. use. FDA summaries for Saige-Dx describe concurrent reading-aid use for qualified interpreting physicians reviewing screening DBT mammograms with compatible hardware.
Best for
Breast imaging programs evaluating FDA-cleared mammography AI alongside worklist, density, risk, and operations modules while keeping interpreting physicians accountable for final reads.
First check
Which Breast Suite module is in scope: Saige-Dx, density assessment, safeguard review, risk assessment, viewer, breast ultrasound, or another DeepHealth component.
Hologic describes Genius AI Detection as deep-learning software for breast tomosynthesis lesion detection, and FDA records list Hologic Genius AI Detection 2.0 clearances including K221449, K230096, and K243341 under radiological computer assisted detection or diagnosis software.
Best for
Breast imaging programs already standardized on Hologic 3D mammography that need product-specific FDA and workflow review for CAD support.
First check
Which version is being evaluated: Genius AI Detection, Genius AI Detection 2.0, CC-MLO Correlation, or another local package.
Sources
4 official sources
Official source trail for this workflow
Open these vendor, documentation, privacy, or regulatory sources before relying on product claims, especially for FDA status, PHI handling, deployment model, and intended use.
Find the best AI for medical workflows by matching the tool to documentation, questions, diagnosis support, research, coding, billing, imaging, or practice operations.
Understand AI for medical diagnosis, including validation evidence, FDA status, clinical supervision, and why patient-specific diagnosis should not rely on general chatbots.
